Silence Therapeutics plc (SLNCF)

Silence Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.56	43.26	31.64	21.66	16.81
Revenue Growth (YoY)	-98.71%	36.71%	46.12%	28.82%	124.73%
Cost of Revenue	0.22	11.81	12.87	13.46	10.1
Gross Profit	0.34	31.45	18.78	8.19	6.71
Selling, General & Admin	22.34	26.88	26.22	25.68	27.09
Research & Development	60.29	54.15	44.99	33.73	41.66
Operating Expenses	82.63	81.03	71.21	59.41	68.75
Operating Income	-82.29	-49.58	-52.43	-51.22	-62.03
Interest Expense	-	-	-	-	-0.01
Interest & Investment Income	0.02	0.7	-	-	0.01
Currency Exchange Gain (Loss)	-8.47	0.65	-2.64	1.29	-0.06
Other Non Operating Income (Expenses)	3.47	3.77	1.8	0.28	-
EBT Excluding Unusual Items	-87.28	-44.46	-53.27	-49.65	-62.09
Merger & Restructuring Charges	-1.32	-	-	-	-
Pretax Income	-88.6	-44.46	-53.27	-49.65	-62.09
Income Tax Expense	0.01	0.85	0.96	0.69	-8.73
Net Income	-88.61	-45.31	-54.23	-50.33	-53.36
Net Income to Common	-88.61	-45.31	-54.23	-50.33	-53.36
Shares Outstanding (Basic)	47	46	37	32	30
Shares Outstanding (Diluted)	47	46	37	32	30
Shares Change (YoY)	2.12%	24.69%	15.21%	8.58%	8.78%
EPS (Basic)	-1.88	-0.98	-1.46	-1.56	-1.80
EPS (Diluted)	-1.88	-0.98	-1.46	-1.56	-1.80
Free Cash Flow	-62.33	-67.85	-49.52	-57.22	7.44
Free Cash Flow Per Share	-1.32	-1.47	-1.33	-1.78	0.25
Gross Margin	61.54%	72.70%	59.34%	37.83%	39.94%
Operating Margin	-14720.93%	-114.62%	-165.70%	-236.53%	-369.02%
Profit Margin	-15851.88%	-104.74%	-171.37%	-232.44%	-317.44%
Free Cash Flow Margin	-11149.55%	-156.85%	-156.49%	-264.22%	44.26%
EBITDA	-81.74	-48.99	-51.81	-50.62	-61.69
EBITDA Margin	-	-113.25%	-163.74%	-233.78%	-
D&A For EBITDA	0.56	0.59	0.62	0.6	0.34
EBIT	-82.29	-49.58	-52.43	-51.22	-62.03
EBIT Margin	-	-114.62%	-165.70%	-236.53%	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.